Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 11, 2004Journal of Clinical Oncology

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMark AyersUlsan College
W. Fraser Symmans
W. Fraser SymmansUniversity of Southern CaliforniaJSJames StecAbbVie (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ayers et al. (2004) studied this question.

synapsesocial.com/papers/6a0fbfa22badbc352afea60chttps://doi.org/10.1200/jco.2004.05.166
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring1999 · 11,648 citations
  2. 2Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy1999 · 1,344 citations
  3. 3Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells.1990 · 173 citations
  4. 4Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer2003 · 1,307 citations
  5. 5Statistical Learning Theory1999 · 26,774 citations